Search Result
Results for "
Chimeric Antibody
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P9913
-
-
-
- HY-P99628
-
|
|
EGFR
|
Cancer
|
|
Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .
|
-
-
- HY-P99362
-
|
Anti-MUC5AC Reference Antibody (ensituximab); NEO-102
|
Mucin
|
Cancer
|
|
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
|
-
-
- HY-P990012
-
-
-
- HY-P9913A
-
|
|
CD20
|
Inflammation/Immunology
Cancer
|
|
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
|
-
-
- HY-P99309
-
|
BSYX-A 110; Anti-S. Epidermidis LTA Recombinant Antibody
|
Bacterial
|
Infection
|
|
Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis .
|
-
-
- HY-P990833
-
|
|
Mesothelin
|
Others
|
|
Anti-Mesothelin Antibody (YP218) is a kind of rabbit IgG chimeric antibody, targeting to human Mesothelin.
|
-
-
- HY-P991037
-
-
-
- HY-P99898
-
|
|
Bacterial
|
Others
|
|
Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1 .
|
-
-
- HY-P990938
-
-
-
- HY-P990847
-
|
|
E-Selectin
|
Others
|
|
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human E-Selectin. The recommend isotype control of Anti-E-Selectin Antibody (CL2): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
-
- HY-P99686
-
|
c4G7-N
|
Filovirus
|
Infection
|
|
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody .
|
-
-
- HY-P990850
-
|
|
c-Myc
|
Others
|
|
Anti-c-myc Antibody (9E10) is a kind of mouse IgG1 chimeric antibody, targeting to human c-myc. The recommend isotype control of Anti-c-myc Antibody (9E10): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990865
-
|
|
CD28
|
Others
|
|
Anti-CD28 Antibody (9.3) is a kind of mouse IgG2a chimeric antibody, targeting to human CD28. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
-
- HY-P990840
-
|
|
Glycoprotein VI
|
Others
|
|
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990873
-
|
|
DNA/RNA Synthesis
|
Others
|
|
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to human BRCA1. The recommend isotype control of Anti-BRCA1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990874
-
|
|
HIV
|
Infection
|
|
Anti-HIV gp120 Antibody (55-36) is a kind of mouse IgG1κ chimeric antibody, targeting to HIV gp120. The recommend isotype control of Anti-HIV gp120 Antibody (55-36): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P99868
-
|
MGD 011
|
CD19
|
Others
Cancer
|
|
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
|
-
-
- HY-P990839
-
|
|
IFNAR
|
Others
|
|
Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody, targeting to human IFNγ. The recommend isotype control of Anti-IFNγ Antibody (B133.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990842
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC-2. The recommend isotype control of Anti-GPC-2 Antibody (CT3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990870
-
|
|
CD19
|
Others
|
|
Anti-CD19 Antibody (4G7) is a kind of mouse IgG1 chimeric antibody, targeting to human CD19. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P99023
-
|
G250; cG250
|
Carbonic Anhydrase
|
Cancer
|
|
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
|
-
-
- HY-108852
-
|
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
-
-
- HY-P990907
-
-
-
- HY-P990939
-
-
-
- HY-P990843
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-Glycophorin A (type M) Antibody (6A7M) is a kind of mouse IgG1, κ chimeric antibody, targeting to human Glycophorin A (type M). The recommend isotype control of Anti-Glycophorin A (type M) Antibody (6A7M): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990856
-
|
|
Transferrin Receptor
|
Others
|
|
Anti-CD71 Antibody (OKT-9) is a kind of mouse IgG1κ chimeric antibody, targeting to human CD71. The recommend isotype control of Anti-CD71 Antibody (OKT-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990859
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a, κ chimeric antibody, targeting to human CD44. The recommend isotype control of Anti-CD44 Antibody (Hermes-1): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
-
-
- HY-P99883
-
|
SAR156597
|
Interleukin Related
|
Others
|
|
Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .
|
-
-
- HY-P99832
-
|
c13C6-FR1
|
Filovirus
|
Infection
|
|
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
|
-
-
- HY-P990084
-
|
|
IGF-1R
|
Cancer
|
|
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody .
|
-
-
- HY-P990827
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-TROP-2 Antibody (Pr1E11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human TROP-2. The recommend isotype control of Anti-TROP-2 Antibody (Pr1E11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990832
-
|
|
MHC
|
Others
|
|
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human MHC Class I. The recommend isotype control of Anti-MHC Class I Antibody (W6/32): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
-
- HY-P990836
-
|
|
Interleukin Related
|
Others
|
|
Anti-IL-9 Antibody (MH9A4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human IL-9. The recommend isotype control of Anti-IL-9 Antibody (MH9A4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
-
- HY-P990861
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD4. The recommend isotype control of Anti-CD4 Antibody (OKT-4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
-
- HY-P990868
-
|
|
CD2
|
Others
|
|
Anti-CD2 Antibody (CB.219) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD2. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
-
- HY-P99892
-
|
PR-1594407; DC-1630423
|
EGFR
|
Others
|
|
Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
-
-
- HY-P990920
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .
|
-
-
- HY-P99896
-
|
|
EGFR
CD3
|
Others
Cancer
|
|
Runimotamab is an IgG1-κ humanized chimeric antibody targeting CD3E and HER2 .
|
-
-
- HY-P990855
-
|
|
Integrin
|
Others
|
|
Anti-CD8α Antibody (OKT-8) is a kind of mouse IgG2a chimeric antibody, targeting to human CD8α. The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
-
- HY-P99607
-
|
IDEC-151
|
HIV
|
Inflammation/Immunology
|
|
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
|
-
-
- HY-P990929
-
|
|
Mesothelin
|
Inflammation/Immunology
|
|
HY-P990929 is an MSLN-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P990957
-
|
BCA-101; FMAB2
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990957 is an EGFR-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P990851
-
|
|
c-Kit
|
Others
|
|
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human c-Kit/CD117. The recommend isotype control of Anti-c-Kit/CD117 Antibody (SR-1): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
-
- HY-P990852
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CEACAM7 Antibody (P3-7B) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM7. The recommend isotype control of Anti-CEACAM7 Antibody (P3-7B): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990858
-
|
|
CD47
|
Others
|
|
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD47. The recommend isotype control of Anti-CD47 Antibody (B6.H12): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990862
-
|
|
CD3
|
Others
|
|
Anti-CD326/EpCAM Antibody (Ber-EP4) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD326/EpCAM. The recommend isotype control of Anti-CD326/EpCAM Antibody (Ber-EP4): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P990867
-
|
|
Insulin Receptor
|
Others
|
|
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a kind of mouse IgG1 chimeric antibody, targeting to human CD220/Insulin Receptor. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
-
- HY-P99538
-
|
LFB-R603; TG-1101; TGTX-1101
|
CD20
|
Cancer
|
|
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
|
-
-
- HY-P990908
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990908 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990914
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990914 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990837
-
|
|
Interleukin Related
|
Others
|
|
Anti-IL-4 Antibody (MP4-25D2) is a kind of rat IgG1, κ chimeric antibody, targeting to human IL-4. The recommend isotype control of Anti-IL-4 Antibody (MP4-25D2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
-
- HY-P99030
-
|
|
EGFR
|
Cancer
|
|
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
|
-
- HY-P990935
-
-
- HY-P9934
-
|
C7E3
|
Integrin
|
Cardiovascular Disease
|
|
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
|
-
- HY-P99306
-
|
DS 1024
|
EGFR
|
Cancer
|
|
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
|
-
- HY-P990831
-
|
|
Mucin
|
Others
|
|
Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3, κ chimeric antibody, targeting to human MUC1/CD227. The recommend isotype control of Anti-MUC1/CD227 Antibody (C595 (NCRC48)): Mouse IgG3 kappa, Isotype Control (HY-P99985).
|
-
- HY-P990854
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CEACAM1/3/5/6/8 Antibody (6G5j) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM1/3/5/6/8. The recommend isotype control of Anti-CEACAM1/3/5/6/8 Antibody (6G5j): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990955
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990829
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-NKG2D/CD314 Antibody (1D11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human NKG2D/CD314. The recommend isotype control of Anti-NKG2D/CD314 Antibody (1D11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P9970
-
-
- HY-P99351
-
|
Anti-MMP9 Reference Antibody (andecaliximab)
|
MMP
|
Cancer
|
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-P99321
-
|
BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
|
-
- HY-P990844
-
|
|
Complement System
|
Others
|
|
Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GC1q R/C1QBP. The recommend isotype control of Anti-GC1q R/C1QBP Antibody (60.11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990857
-
|
|
Integrin
|
Others
|
|
Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD54/ICAM-1. The recommend isotype control of Anti-CD54/ICAM-1 Antibody (R6-5-D6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990871
-
|
|
Integrin
|
Others
|
|
Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody, targeting to human CD11a/LFA-1α. The recommend isotype control of Anti-CD11a/LFA-1α Antibody (R7-1): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990574
-
|
|
Histone Methyltransferase
|
Inflammation/Immunology
|
|
Derlotuximab is a CHO-expressed, scFv-Fc (huIgG1) type chimeric antibody that targets Histone H1. The predicted molecular weight (MW) of Derlotuximab is 145.1 kDa. The isotype control for Derlotuximab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99680
-
|
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
-
- HY-P990607
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P9970A
-
|
Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)
|
TNF Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
|
-
- HY-P99238
-
|
|
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .
|
-
- HY-P99333
-
|
M200; Eos 200-4
|
Integrin
|
Cardiovascular Disease
Cancer
|
|
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
|
-
- HY-P99008
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis . Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist .
|
-
- HY-P3149
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P3149B
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P3203A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-P3149A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-141607
-
|
BT-062; nBT062-DM4
|
Antibody-Drug Conjugates (ADCs)
Bacterial
|
Cancer
|
|
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .
|
-
- HY-153085
-
|
|
CD19
|
Inflammation/Immunology
Cancer
|
|
CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
|
-
- HY-P990953
-
-
- HY-P990912
-
-
- HY-153084
-
|
|
CD19
|
Inflammation/Immunology
Cancer
|
|
CD19 CAR mRNA (Mouse) will express mouse CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
|
-
- HY-153084A
-
|
|
CD19
|
Cancer
|
|
CD19 CAR mRNA (Human) will express Human CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
|
-
- HY-P99530
-
|
AGT-181; HIRMAb-IDUA
|
Insulin Receptor
|
Metabolic Disease
|
|
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
|
-
- HY-P990928
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody .
|
-
- HY-153234
-
|
|
CD19
Liposome
|
Inflammation/Immunology
Cancer
|
|
CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .
|
-
- HY-153233
-
|
|
CD19
Liposome
|
Inflammation/Immunology
Cancer
|
|
CD19 car mRNA (Mouse)-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .
|
-
- HY-129937
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
(S)-GNE-987 (compound 4), the GNE-987 (a chimeric BET degrader) hydroxy-proline epimer, abrogates binding to von Hippel-Lindau and does not degrade BRD4 protein. (S)-GNE-987 binds to the BRD4 BD1(IC50=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC) .
|
-
- HY-P9905
-
Cetuximab
Maximum Cited Publications
36 Publications Verification
C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
- HY-P9976
-
|
|
Apoptosis
|
Cancer
|
|
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
|
-
- HY-P99006
-
|
MORab-009
|
Mesothelin
|
Cancer
|
|
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .
|
-
- HY-P99054
-
|
|
Transmembrane Glycoprotein
ADC Antibody
|
Cancer
|
|
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative) .
|
-
- HY-P9932
-
|
ETI 204
|
Bacterial
|
Infection
Cardiovascular Disease
|
|
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
|
-
- HY-P99115
-
|
ASC 22; KN 035
|
PD-1/PD-L1
|
Cancer
|
|
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .
|
-
- HY-P99151
-
-
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research .
|
-
- HY-P99239
-
|
HUJ-591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
-
- HY-P99225
-
|
M9346A
|
Antifolate
|
Cancer
|
|
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
|
-
- HY-P9956
-
|
CNTO-328
|
Interleukin Related
|
Cancer
|
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
|
-
- HY-P99338
-
|
CTL019
|
CD19
|
Inflammation/Immunology
Cancer
|
|
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .
|
-
- HY-P99374
-
|
Anti-TSPAN26/CD37 Reference Antibody (naratuximab)
|
ADC Antibody
|
Cancer
|
|
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
|
-
- HY-P99329
-
|
Anti-Human CD33 Recombinant Antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
|
-
- HY-P99381
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
|
-
- HY-P99413
-
|
ASP1650
|
HCV
|
Cancer
|
|
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 + ovarian and testicular cancer cell lines .
|
-
- HY-P99501
-
|
HS006
|
CD20
|
Cancer
|
|
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .
|
-
- HY-P99520
-
|
CaCP-29, IFX-1
|
Complement System
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
|
-
- HY-P99535
-
|
SCTA01
|
SARS-CoV
|
Cancer
|
|
Upanovimab (SCTA01) is a monoclonal antibody that targets the SARS-CoV-2 S protein .
|
-
- HY-P99526
-
-
- HY-P99462
-
|
CDX-0159; CDX-0158
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
-
- HY-P99475
-
|
MSB-2311
|
PD-1/PD-L1
|
Cancer
|
|
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
|
-
- HY-P99784
-
|
|
Filovirus
|
Infection
|
|
Porgaviximab is a monoclonal antibody that can be used Ebola infection research .
|
-
- HY-P99494
-
|
TRC105; DE-122
|
TGF-beta/Smad
|
Cancer
|
|
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions .
|
-
- HY-P99555
-
-
- HY-P99625
-
|
SAR441344; INX-021
|
TNF Receptor
|
Inflammation/Immunology
|
|
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sjögren’s syndrome and type I diabetes research .
|
-
- HY-P99324
-
|
Anti-Human EGFR Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
-
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
-
- HY-P99895
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
-
- HY-P99952
-
|
SCT400
|
CD20
|
Cancer
|
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
|
-
- HY-P99961
-
|
JS004
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer .
|
-
- HY-P99648
-
|
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
|
-
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
-
- HY-P99684
-
|
J2898A
|
EGFR
|
Cancer
|
|
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .
|
-
- HY-P99711
-
|
RB4v1.2
|
CD19
|
Cancer
|
|
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) .
|
-
- HY-P99512
-
|
UCB-7858
|
Glutaminase
|
Inflammation/Immunology
|
|
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab has potential application in renal transplant .
|
-
- HY-P99761
-
|
XmAb5871
|
CD19
Apoptosis
|
Inflammation/Immunology
|
|
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
|
-
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
-
- HY-P99945
-
-
- HY-P99947
-
|
XVR011
|
SARS-CoV
|
Infection
|
|
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .
|
-
- HY-P99100
-
|
CTL-002
|
PD-1/PD-L1
|
Cancer
|
|
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors .
|
-
- HY-P9998
-
|
UB421
|
HIV
|
Cancer
|
|
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
|
-
- HY-P99105
-
-
- HY-P9976A
-
|
|
CD38
|
Cancer
|
|
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .
|
-
- HY-P990083
-
|
|
TNF Receptor
|
Cancer
|
|
Tegoprubart is a monoclonal antibody directed against CD40 ligand (CD40L), a key mediator of costimulation. Inhibition of CD40L reduces cellular and antibody-mediated immunity and creates a more tolerant immune environment. Tegoprubart was demonstrated to have in vivo efficacy in transplantation animal models.
|
-
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .
|
-
- HY-P990695
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
|
-
- HY-P990729
-
|
|
CD19
|
Inflammation/Immunology
|
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990734
-
-
- HY-P990748
-
-
- HY-P990781
-
|
SM03
|
CD22
|
Inflammation/Immunology
|
|
Suciraslimab is an anti-CD22 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99643A
-
|
|
Dan family
|
Cancer
|
|
Ginisortamab (Mouse IgG1) is the anti-Gremlin-1 monoclonal antibody with mouse IgG1. Ginisortamab (Mouse IgG1) can be used in research of gastrointestinal (GI) tumors .
|
-
- HY-P99849
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
|
-
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
-
- HY-P99029
-
|
Hu5F9-G4
|
CD47
|
Cancer
|
|
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
|
-
- HY-P99050
-
-
- HY-P99108
-
-
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
-
- HY-P99169
-
|
TJ004309
|
CD73
|
Cancer
|
|
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
|
-
- HY-P99229
-
|
|
ADC Antibody
|
Cancer
|
|
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .
|
-
- HY-P99177
-
|
|
SARS-CoV
|
Infection
Cardiovascular Disease
|
|
Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research .
|
-
- HY-145626
-
|
BA302
|
ADC Antibody
|
Cancer
|
|
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC .
|
-
- HY-P99211
-
|
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
-
- HY-P99393
-
|
MEDI 0562; Tavolimab
|
TNF Receptor
|
Cancer
|
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
|
-
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
-
- HY-P99396
-
|
BI 655130
|
Interleukin Related
|
Inflammation/Immunology
|
|
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .
|
-
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
-
- HY-P99521
-
|
XmAb14045
|
CD3
|
Cancer
|
|
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .
|
-
- HY-P99481
-
|
NEOD001
|
Amyloid-β
|
Neurological Disease
|
|
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
|
-
- HY-P99470
-
|
GEN1029
|
TNF Receptor
Apoptosis
|
Cancer
|
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
|
-
- HY-P99855
-
|
BCD-132
|
CD20
|
Inflammation/Immunology
|
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .
|
-
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
-
- HY-P99807
-
|
BCD-100
|
PD-1/PD-L1
|
Cancer
|
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
-
- HY-P99619
-
|
SCT-I10A
|
PD-1/PD-L1
|
Cancer
|
|
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
|
-
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
-
- HY-P99404
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion .
|
-
- HY-P99635
-
|
GZ-402668
|
NF-κB
|
Cancer
|
|
Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody .
|
-
- HY-P99638
-
-
- HY-P99941
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
-
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
-
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
-
- HY-P99652
-
|
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
-
- HY-P99965
-
|
SKY59; RO7112689
|
Complement System
|
Cardiovascular Disease
Metabolic Disease
|
|
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
|
-
- HY-P99708
-
|
ABBV-151; ARGX-115
|
TGF-beta/Smad
|
Cancer
|
|
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
|
-
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
-
- HY-P99659
-
|
ANB 019
|
Interleukin Related
|
Inflammation/Immunology
|
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
|
-
- HY-P99715
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .
|
-
- HY-P99834
-
|
89Zr-Df-IAB22M2C
|
Fluorescent Dye
|
Cancer
|
|
Crefmirlimab (89Zr-Df-IAB22M2C) is an anti-human CD8 probe targeting CD8 antigen, which can be used in the diagnosis of various cancers .
|
-
- HY-P99736
-
|
BI-754111
|
LAG-3
|
Cancer
|
|
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
|
-
- HY-P99740
-
|
|
CD276/B7-H3
ADC Antibody
|
Cancer
|
|
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
-
- HY-P99822
-
|
SHR-1209
|
PCSK9
LDLR
|
Metabolic Disease
|
|
Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .
|
-
- HY-P99754
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .
|
-
- HY-P99727
-
|
SYN023
|
RABV
|
Infection
|
|
Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies .
|
-
- HY-P99778
-
|
MORAb-004
|
EGFR
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
-
- HY-P990018
-
|
MK-5890
|
TNF Receptor
|
Cancer
|
|
Boserolimab (MK-5890) is a humanized agonist monoclonal antibody that binds to CD27 to provide a costimulatory signal that enhances T-cell–mediated responses .
|
-
- HY-P99948
-
-
- HY-P99454
-
|
ABBV-838
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
|
-
- HY-P99117
-
|
AK104
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99166
-
|
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
|
-
- HY-P99350
-
|
AMG 910; Anti-Human CD3xClaudin18 2
|
CD3
|
Cancer
|
|
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
|
-
- HY-P99575
-
|
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
-
- HY-P99601
-
|
BFCR 4350A; RG 6160; RO 7187797
|
CD3
|
Neurological Disease
Cancer
|
|
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
|
-
- HY-P99354
-
|
Anti-Human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
-
- HY-P99392
-
|
|
CD3
|
Cancer
|
|
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
|
-
- HY-P99523
-
|
AMG 199
|
CD3
|
Cancer
|
|
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .
|
-
- HY-P99517
-
|
JNJ-63898081
|
CD3
|
Cancer
|
|
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .
|
-
- HY-P99562
-
|
XmAb-18087
|
CD3
|
Cancer
|
|
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
|
-
- HY-P99430
-
|
EM901; CC-93269
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Alnuctamab (EM901) is an asymmetric 2-arm, humanized IgG T-cell engager (TCE). Alnuctamab can be used for immune research .
|
-
- HY-P99958
-
|
AMV-564; TandAb T564
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
|
-
- HY-P99676
-
|
SI-B001
|
EGFR
|
Cancer
|
|
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
|
-
- HY-P99675
-
|
AK112
|
PD-1/PD-L1
VEGFR
|
Cancer
|
|
Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research .
|
-
- HY-P99679
-
-
- HY-P99798
-
|
AMG 420; BI-836909
|
CD3
|
Cancer
|
|
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
|
-
- HY-P99802
-
|
BAY 2010112; AMG 212
|
CD3
|
Cancer
|
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-P99814
-
|
AMG-701
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
|
-
- HY-P99757
-
|
Hu3F8-BsAb
|
CD2
CD3
|
Cancer
|
|
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .
|
-
- HY-P99762
-
|
MGD009
|
CD3
|
Cancer
|
|
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
|
-
- HY-P99776
-
|
XmAb-13676
|
CD20
CD3
|
Cancer
|
|
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
|
-
- HY-P99931
-
|
GEN3013
|
CD3
CD20
|
Cancer
|
|
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
|
-
- HY-P99614
-
|
BFKB8488A
|
FGFR
|
Metabolic Disease
|
|
Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .
|
-
- HY-P990054
-
|
|
CD20
|
Cancer
|
|
Eramkafusp Alfa is a human IgG1 antibody targeting the mouse B lymphocyte CD20 antigen MS4A1 .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-153234
-
|
|
Drug Delivery
|
|
CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .
|
-
- HY-153233
-
|
|
Drug Delivery
|
|
CD19 car mRNA (Mouse)-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3149B
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P3203A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-P3149
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P3203
-
|
|
Peptides
|
Inflammation/Immunology
|
|
DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-P3149A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9913
-
-
- HY-P99628
-
|
|
EGFR
|
Cancer
|
|
Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .
|
-
- HY-P99362
-
|
Anti-MUC5AC Reference Antibody (ensituximab); NEO-102
|
Mucin
|
Cancer
|
|
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
|
-
- HY-P990012
-
-
- HY-P99899
-
-
- HY-P990833
-
|
|
Mesothelin
|
Others
|
|
Anti-Mesothelin Antibody (YP218) is a kind of rabbit IgG chimeric antibody, targeting to human Mesothelin.
|
-
- HY-P991037
-
-
- HY-P99898
-
|
|
Bacterial
|
Others
|
|
Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1 .
|
-
- HY-P990010
-
-
- HY-P990938
-
-
- HY-P9913A
-
|
|
CD20
|
Inflammation/Immunology
Cancer
|
|
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
|
-
- HY-P99309
-
|
BSYX-A 110; Anti-S. Epidermidis LTA Recombinant Antibody
|
Bacterial
|
Infection
|
|
Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis .
|
-
- HY-P990847
-
|
|
E-Selectin
|
Others
|
|
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human E-Selectin. The recommend isotype control of Anti-E-Selectin Antibody (CL2): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P99686
-
|
c4G7-N
|
Filovirus
|
Infection
|
|
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody .
|
-
- HY-P990850
-
|
|
c-Myc
|
Others
|
|
Anti-c-myc Antibody (9E10) is a kind of mouse IgG1 chimeric antibody, targeting to human c-myc. The recommend isotype control of Anti-c-myc Antibody (9E10): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990865
-
|
|
CD28
|
Others
|
|
Anti-CD28 Antibody (9.3) is a kind of mouse IgG2a chimeric antibody, targeting to human CD28. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990826
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-YB-1 Antibody (21A3) is a kind of mouse IgG1 chimeric antibody, targeting to human YB-1. The recommend isotype control of Anti-YB-1 Antibody (21A3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990830
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-MUC16 Antibody (VK8) is a kind of mouse IgG1, κ chimeric antibody, targeting to human MUC16. The recommend isotype control of Anti-MUC16 Antibody (VK8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990840
-
|
|
Glycoprotein VI
|
Others
|
|
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990873
-
|
|
DNA/RNA Synthesis
|
Others
|
|
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to human BRCA1. The recommend isotype control of Anti-BRCA1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990874
-
|
|
HIV
|
Infection
|
|
Anti-HIV gp120 Antibody (55-36) is a kind of mouse IgG1κ chimeric antibody, targeting to HIV gp120. The recommend isotype control of Anti-HIV gp120 Antibody (55-36): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P99868
-
|
MGD 011
|
CD19
|
Others
Cancer
|
|
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
|
-
- HY-P990839
-
|
|
IFNAR
|
Others
|
|
Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody, targeting to human IFNγ. The recommend isotype control of Anti-IFNγ Antibody (B133.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990842
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC-2. The recommend isotype control of Anti-GPC-2 Antibody (CT3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990870
-
|
|
CD19
|
Others
|
|
Anti-CD19 Antibody (4G7) is a kind of mouse IgG1 chimeric antibody, targeting to human CD19. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P99023
-
|
G250; cG250
|
Carbonic Anhydrase
|
Cancer
|
|
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
|
-
- HY-108852
-
|
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
-
- HY-P990907
-
-
- HY-P990939
-
-
- HY-P990843
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-Glycophorin A (type M) Antibody (6A7M) is a kind of mouse IgG1, κ chimeric antibody, targeting to human Glycophorin A (type M). The recommend isotype control of Anti-Glycophorin A (type M) Antibody (6A7M): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990845
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Ganglioside GD2 Antibody (14G2a) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human Ganglioside GD2. The recommend isotype control of Anti-Ganglioside GD2 Antibody (14G2a): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990846
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Fy3 Antibody (MIMA-29) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human Fy3. The recommend isotype control of Anti-Fy3 Antibody (MIMA-29): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990856
-
|
|
Transferrin Receptor
|
Others
|
|
Anti-CD71 Antibody (OKT-9) is a kind of mouse IgG1κ chimeric antibody, targeting to human CD71. The recommend isotype control of Anti-CD71 Antibody (OKT-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990859
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a, κ chimeric antibody, targeting to human CD44. The recommend isotype control of Anti-CD44 Antibody (Hermes-1): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
-
- HY-P990864
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human CD3. The recommend isotype control of Anti-CD3 Antibody (OKT-3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990869
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD1a Antibody (OKT-6) is a kind of mouse IgG1 chimeric antibody, targeting to human CD1a. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P99883
-
|
SAR156597
|
Interleukin Related
|
Others
|
|
Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .
|
-
- HY-P99832
-
|
c13C6-FR1
|
Filovirus
|
Infection
|
|
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
|
-
- HY-P990084
-
|
|
IGF-1R
|
Cancer
|
|
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody .
|
-
- HY-P990827
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-TROP-2 Antibody (Pr1E11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human TROP-2. The recommend isotype control of Anti-TROP-2 Antibody (Pr1E11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990832
-
|
|
MHC
|
Others
|
|
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human MHC Class I. The recommend isotype control of Anti-MHC Class I Antibody (W6/32): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990836
-
|
|
Interleukin Related
|
Others
|
|
Anti-IL-9 Antibody (MH9A4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human IL-9. The recommend isotype control of Anti-IL-9 Antibody (MH9A4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
- HY-P990860
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD40 Antibody (G28.5) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD40. The recommend isotype control of Anti-CD40 Antibody (G28.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990861
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD4. The recommend isotype control of Anti-CD4 Antibody (OKT-4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
- HY-P990868
-
|
|
CD2
|
Others
|
|
Anti-CD2 Antibody (CB.219) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD2. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
- HY-P99892
-
|
PR-1594407; DC-1630423
|
EGFR
|
Others
|
|
Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P990019
-
-
- HY-P99873
-
|
KM 871; KW 2871
|
Inhibitory Antibodies
|
Others
|
|
Ecromeximab (KM 871; KW 2871) is a mouse-derived IgG-κ chimeric antibody targeting ganglioside GD3. Ecromeximab is expressed by YB2/0 rat hybridoma cells .
|
-
- HY-P990920
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .
|
-
- HY-P99896
-
|
|
EGFR
CD3
|
Others
Cancer
|
|
Runimotamab is an IgG1-κ humanized chimeric antibody targeting CD3E and HER2 .
|
- HY-P990855
-
|
|
Integrin
|
Others
|
|
Anti-CD8α Antibody (OKT-8) is a kind of mouse IgG2a chimeric antibody, targeting to human CD8α. The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P99607
-
|
IDEC-151
|
HIV
|
Inflammation/Immunology
|
|
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
|
- HY-P990929
-
|
|
Mesothelin
|
Inflammation/Immunology
|
|
HY-P990929 is an MSLN-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990957
-
|
BCA-101; FMAB2
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990957 is an EGFR-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990838
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-IL-12 p70 Antibody (20C2) is a kind of rat IgG1, κ chimeric antibody, targeting to human IL-12 p70. The recommend isotype control of Anti-IL-12 p70 Antibody (20C2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990851
-
|
|
c-Kit
|
Others
|
|
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human c-Kit/CD117. The recommend isotype control of Anti-c-Kit/CD117 Antibody (SR-1): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990852
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CEACAM7 Antibody (P3-7B) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM7. The recommend isotype control of Anti-CEACAM7 Antibody (P3-7B): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990853
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM5. The recommend isotype control of Anti-CEACAM5 Antibody (4H11-8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990997
-
- HY-P990858
-
|
|
CD47
|
Others
|
|
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD47. The recommend isotype control of Anti-CD47 Antibody (B6.H12): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990862
-
|
|
CD3
|
Others
|
|
Anti-CD326/EpCAM Antibody (Ber-EP4) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD326/EpCAM. The recommend isotype control of Anti-CD326/EpCAM Antibody (Ber-EP4): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990867
-
|
|
Insulin Receptor
|
Others
|
|
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a kind of mouse IgG1 chimeric antibody, targeting to human CD220/Insulin Receptor. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P99538
-
|
LFB-R603; TG-1101; TGTX-1101
|
CD20
|
Cancer
|
|
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
|
- HY-P990908
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990908 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990914
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990914 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990837
-
|
|
Interleukin Related
|
Others
|
|
Anti-IL-4 Antibody (MP4-25D2) is a kind of rat IgG1, κ chimeric antibody, targeting to human IL-4. The recommend isotype control of Anti-IL-4 Antibody (MP4-25D2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990848
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human CTLA-4/CD152. The recommend isotype control of Anti-CTLA-4/CD152 Antibody (BN13): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990863
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD32/FcγRIIA Antibody (IV.3) is a kind of mouse IgG2b chimeric antibody, targeting to human CD32/FcγRIIA. The recommend isotype control of Anti-CD32/FcγRIIA Antibody (IV.3): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990872
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CA19-9 Antibody (1116-NS-19-9) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CA19-9. The recommend isotype control of Anti-CA19-9 Antibody (1116-NS-19-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990934
-
- HY-P99030
-
|
|
EGFR
|
Cancer
|
|
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
|
- HY-P990916
-
- HY-P990935
-
- HY-P9934
-
|
C7E3
|
Integrin
|
Cardiovascular Disease
|
|
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
|
- HY-P99306
-
|
DS 1024
|
EGFR
|
Cancer
|
|
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
|
- HY-P990831
-
|
|
Mucin
|
Others
|
|
Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3, κ chimeric antibody, targeting to human MUC1/CD227. The recommend isotype control of Anti-MUC1/CD227 Antibody (C595 (NCRC48)): Mouse IgG3 kappa, Isotype Control (HY-P99985).
|
- HY-P990854
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CEACAM1/3/5/6/8 Antibody (6G5j) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM1/3/5/6/8. The recommend isotype control of Anti-CEACAM1/3/5/6/8 Antibody (6G5j): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990952
-
- HY-P990955
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990829
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-NKG2D/CD314 Antibody (1D11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human NKG2D/CD314. The recommend isotype control of Anti-NKG2D/CD314 Antibody (1D11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990834
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-MAGEC2/CT10 Antibody (LX-CT10.5) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human MAGEC2/CT10. The recommend isotype control of Anti-MAGEC2/CT10 Antibody (LX-CT10.5): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990948
-
- HY-P9970
-
- HY-P99351
-
|
Anti-MMP9 Reference Antibody (andecaliximab)
|
MMP
|
Cancer
|
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
|
- HY-P99321
-
|
BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
|
- HY-P990844
-
|
|
Complement System
|
Others
|
|
Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GC1q R/C1QBP. The recommend isotype control of Anti-GC1q R/C1QBP Antibody (60.11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990849
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CSF1R/CD115 Antibody (2-4A5-4) is a kind of rat IgG1, κ chimeric antibody, targeting to human CSF1R/CD115. The recommend isotype control of Anti-CSF1R/CD115 Antibody (2-4A5-4): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990857
-
|
|
Integrin
|
Others
|
|
Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD54/ICAM-1. The recommend isotype control of Anti-CD54/ICAM-1 Antibody (R6-5-D6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990871
-
|
|
Integrin
|
Others
|
|
Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody, targeting to human CD11a/LFA-1α. The recommend isotype control of Anti-CD11a/LFA-1α Antibody (R7-1): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990574
-
|
|
Histone Methyltransferase
|
Inflammation/Immunology
|
|
Derlotuximab is a CHO-expressed, scFv-Fc (huIgG1) type chimeric antibody that targets Histone H1. The predicted molecular weight (MW) of Derlotuximab is 145.1 kDa. The isotype control for Derlotuximab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99680
-
|
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
- HY-P990835
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a kind of mouse IgG1 chimeric antibody, targeting to human LFA-1α/CD11a. The recommend isotype control of Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990866
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD25/IL-2Rα Antibody (7G7B6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD25/IL-2Rα. The recommend isotype control of Anti-CD25/IL-2Rα Antibody (7G7B6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990607
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P9970A
-
|
Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)
|
TNF Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
|
- HY-P990828
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human PD-L1/B7-H1. The recommend isotype control of Anti-PD-L1/B7-H1 Antibody (29E.2A3): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P9933
-
|
APN-311
|
Inhibitory Antibodies
|
Cancer
|
|
Dinutuximab (Unituxin; APN-311) is a chimeric, human-murine, anti-GD2 monoclonal antibody. Dinutuximab potently enlongs event-free survival and overall survival, in high-risk neuroblastoma treatment, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) .
|
- HY-P99238
-
|
|
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .
|
- HY-P99333
-
|
M200; Eos 200-4
|
Integrin
|
Cardiovascular Disease
Cancer
|
|
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
|
- HY-P990310
-
- HY-P99008
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis . Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist .
|
- HY-P99990
-
- HY-P990412
-
- HY-P99992
-
- HY-P99994
-
- HY-P99996
-
- HY-P99998
-
- HY-P99995
-
- HY-P99997
-
- HY-P99987
-
- HY-P99993
-
- HY-141607
-
|
BT-062; nBT062-DM4
|
Antibody-Drug Conjugates (ADCs)
Bacterial
|
Cancer
|
|
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .
|
- HY-P990953
-
- HY-P990912
-
- HY-P99530
-
|
AGT-181; HIRMAb-IDUA
|
Insulin Receptor
|
Metabolic Disease
|
|
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
|
- HY-P990928
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody .
|
- HY-P9905
-
Cetuximab
Maximum Cited Publications
36 Publications Verification
C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
- HY-P9976
-
|
|
Apoptosis
|
Cancer
|
|
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
|
- HY-P99006
-
|
MORab-009
|
Mesothelin
|
Cancer
|
|
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .
|
- HY-P99058
-
|
IMAB362
|
Inhibitory Antibodies
|
Cancer
|
|
Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors .
|
- HY-P99054
-
|
|
Transmembrane Glycoprotein
ADC Antibody
|
Cancer
|
|
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative) .
|
- HY-P9932
-
|
ETI 204
|
Bacterial
|
Infection
Cardiovascular Disease
|
|
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
|
- HY-P99115
-
|
ASC 22; KN 035
|
PD-1/PD-L1
|
Cancer
|
|
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .
|
- HY-P99151
-
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research .
|
- HY-P99239
-
|
HUJ-591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
- HY-P99206
-
|
Naxitamab-gqgk; Humanized 3F8; Hu3F8
|
Inhibitory Antibodies
|
Cancer
|
|
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers .
|
- HY-P99225
-
|
M9346A
|
Antifolate
|
Cancer
|
|
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
|
- HY-P9956
-
|
CNTO-328
|
Interleukin Related
|
Cancer
|
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
|
- HY-P99279
-
|
Anti-Human Phosphatidylserine Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .
|
- HY-P99338
-
|
CTL019
|
CD19
|
Inflammation/Immunology
Cancer
|
|
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .
|
- HY-P99374
-
|
Anti-TSPAN26/CD37 Reference Antibody (naratuximab)
|
ADC Antibody
|
Cancer
|
|
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
|
- HY-P99329
-
|
Anti-Human CD33 Recombinant Antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
|
- HY-P99381
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
|
- HY-P99413
-
|
ASP1650
|
HCV
|
Cancer
|
|
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 + ovarian and testicular cancer cell lines .
|
- HY-P99501
-
|
HS006
|
CD20
|
Cancer
|
|
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .
|
- HY-P99520
-
|
CaCP-29, IFX-1
|
Complement System
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
|
- HY-P99535
-
|
SCTA01
|
SARS-CoV
|
Cancer
|
|
Upanovimab (SCTA01) is a monoclonal antibody that targets the SARS-CoV-2 S protein .
|
- HY-P99438
-
|
KIND-030
|
Inhibitory Antibodies
|
Infection
|
|
Anivovetmab (KIND-030) is an anti-VP2 (parvovirus major capsid protein) monoclonal antibody (IgG2 type). Anivovetmab has the potential to study canine parvovirus infection.
|
- HY-P99526
-
- HY-P99462
-
|
CDX-0159; CDX-0158
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
- HY-P99475
-
|
MSB-2311
|
PD-1/PD-L1
|
Cancer
|
|
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
|
- HY-P99784
-
|
|
Filovirus
|
Infection
|
|
Porgaviximab is a monoclonal antibody that can be used Ebola infection research .
|
- HY-P99582
-
|
ONC-005, OTSA101
|
Inhibitory Antibodies
|
Cancer
|
|
Tabituximab (OTSA101) is a humanized monoclonal antibody against frizzled class receptor 10 (FZD10) .
|
- HY-P99494
-
|
TRC105; DE-122
|
TGF-beta/Smad
|
Cancer
|
|
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions .
|
- HY-P99555
-
- HY-P99625
-
|
SAR441344; INX-021
|
TNF Receptor
|
Inflammation/Immunology
|
|
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sjögren’s syndrome and type I diabetes research .
|
- HY-P99557
-
- HY-P99324
-
|
Anti-Human EGFR Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
- HY-P99895
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
- HY-P99952
-
|
SCT400
|
CD20
|
Cancer
|
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
|
- HY-P99961
-
|
JS004
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer .
|
- HY-P99648
-
|
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
|
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
- HY-P99684
-
|
J2898A
|
EGFR
|
Cancer
|
|
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .
|
- HY-P99711
-
|
RB4v1.2
|
CD19
|
Cancer
|
|
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) .
|
- HY-P99512
-
|
UCB-7858
|
Glutaminase
|
Inflammation/Immunology
|
|
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab has potential application in renal transplant .
|
- HY-P99761
-
|
XmAb5871
|
CD19
Apoptosis
|
Inflammation/Immunology
|
|
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
|
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
- HY-P99791
-
|
SYNT001; ALXN1830
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity .
|
- HY-P99945
-
- HY-P99947
-
|
XVR011
|
SARS-CoV
|
Infection
|
|
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .
|
- HY-P99100
-
|
CTL-002
|
PD-1/PD-L1
|
Cancer
|
|
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors .
|
- HY-P9998
-
|
UB421
|
HIV
|
Cancer
|
|
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
|
- HY-P99105
-
- HY-P9976A
-
|
|
CD38
|
Cancer
|
|
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .
|
- HY-P99800
-
- HY-P990083
-
|
|
TNF Receptor
|
Cancer
|
|
Tegoprubart is a monoclonal antibody directed against CD40 ligand (CD40L), a key mediator of costimulation. Inhibition of CD40L reduces cellular and antibody-mediated immunity and creates a more tolerant immune environment. Tegoprubart was demonstrated to have in vivo efficacy in transplantation animal models.
|
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .
|
- HY-P990695
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
|
- HY-P990729
-
|
|
CD19
|
Inflammation/Immunology
|
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990732
-
- HY-P990734
-
- HY-P990743
-
- HY-P990744
-
- HY-P990748
-
- HY-P990781
-
|
SM03
|
CD22
|
Inflammation/Immunology
|
|
Suciraslimab is an anti-CD22 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99643A
-
|
|
Dan family
|
Cancer
|
|
Ginisortamab (Mouse IgG1) is the anti-Gremlin-1 monoclonal antibody with mouse IgG1. Ginisortamab (Mouse IgG1) can be used in research of gastrointestinal (GI) tumors .
|
- HY-P99849
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
|
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
- HY-P99029
-
|
Hu5F9-G4
|
CD47
|
Cancer
|
|
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
|
- HY-P99050
-
- HY-P99108
-
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
- HY-P99169
-
|
TJ004309
|
CD73
|
Cancer
|
|
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
|
- HY-P99229
-
|
|
ADC Antibody
|
Cancer
|
|
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .
|
- HY-P99177
-
|
|
SARS-CoV
|
Infection
Cardiovascular Disease
|
|
Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research .
|
- HY-145626
-
|
BA302
|
ADC Antibody
|
Cancer
|
|
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC .
|
- HY-P99211
-
|
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
- HY-P99369
-
|
IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)
|
Inhibitory Antibodies
|
Cancer
|
|
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma .
|
- HY-P99393
-
|
MEDI 0562; Tavolimab
|
TNF Receptor
|
Cancer
|
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
|
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
- HY-P99396
-
|
BI 655130
|
Interleukin Related
|
Inflammation/Immunology
|
|
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .
|
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
- HY-P99407
-
|
VX 15/2503
|
Inhibitory Antibodies
|
Neurological Disease
Cancer
|
|
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .
|
- HY-P99521
-
|
XmAb14045
|
CD3
|
Cancer
|
|
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .
|
- HY-P99481
-
|
NEOD001
|
Amyloid-β
|
Neurological Disease
|
|
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
|
- HY-P99470
-
|
GEN1029
|
TNF Receptor
Apoptosis
|
Cancer
|
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
|
- HY-P99855
-
|
BCD-132
|
CD20
|
Inflammation/Immunology
|
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .
|
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
- HY-P99807
-
|
BCD-100
|
PD-1/PD-L1
|
Cancer
|
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
- HY-P99619
-
|
SCT-I10A
|
PD-1/PD-L1
|
Cancer
|
|
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
|
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
- HY-P99488
-
|
JSP-191
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID) .
|
- HY-P99404
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion .
|
- HY-P99635
-
|
GZ-402668
|
NF-κB
|
Cancer
|
|
Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody .
|
- HY-P99638
-
- HY-P99941
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
- HY-P99640
-
|
ABBV-927
|
Inhibitory Antibodies
|
Cancer
|
|
Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer .
|
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
- HY-P99652
-
|
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
- HY-P99959
-
|
MT-3921; rH116A3
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration and can be used for the research of spinal cord injury .
|
- HY-P99965
-
|
SKY59; RO7112689
|
Complement System
|
Cardiovascular Disease
Metabolic Disease
|
|
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
|
- HY-P99708
-
|
ABBV-151; ARGX-115
|
TGF-beta/Smad
|
Cancer
|
|
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
|
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
- HY-P99659
-
|
ANB 019
|
Interleukin Related
|
Inflammation/Immunology
|
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
|
- HY-P99715
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .
|
- HY-P99834
-
|
89Zr-Df-IAB22M2C
|
Fluorescent Dye
|
Cancer
|
|
Crefmirlimab (89Zr-Df-IAB22M2C) is an anti-human CD8 probe targeting CD8 antigen, which can be used in the diagnosis of various cancers .
|
- HY-P99736
-
|
BI-754111
|
LAG-3
|
Cancer
|
|
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
|
- HY-P99740
-
|
|
CD276/B7-H3
ADC Antibody
|
Cancer
|
|
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
- HY-P99822
-
|
SHR-1209
|
PCSK9
LDLR
|
Metabolic Disease
|
|
Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .
|
- HY-P99754
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .
|
- HY-P99727
-
|
SYN023
|
RABV
|
Infection
|
|
Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies .
|
- HY-P99778
-
|
MORAb-004
|
EGFR
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
- HY-P990018
-
|
MK-5890
|
TNF Receptor
|
Cancer
|
|
Boserolimab (MK-5890) is a humanized agonist monoclonal antibody that binds to CD27 to provide a costimulatory signal that enhances T-cell–mediated responses .
|
- HY-P99418
-
- HY-P99910
-
- HY-P99912
-
- HY-P99948
-
- HY-P99454
-
|
ABBV-838
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
|
- HY-P99117
-
|
AK104
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
|
- HY-P99166
-
|
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
|
- HY-P99350
-
|
AMG 910; Anti-Human CD3xClaudin18 2
|
CD3
|
Cancer
|
|
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
|
- HY-P99575
-
|
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
- HY-P99601
-
|
BFCR 4350A; RG 6160; RO 7187797
|
CD3
|
Neurological Disease
Cancer
|
|
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
|
- HY-P99354
-
|
Anti-Human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
- HY-P99392
-
|
|
CD3
|
Cancer
|
|
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
|
- HY-P99523
-
|
AMG 199
|
CD3
|
Cancer
|
|
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .
|
- HY-P99517
-
|
JNJ-63898081
|
CD3
|
Cancer
|
|
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .
|
- HY-P99562
-
|
XmAb-18087
|
CD3
|
Cancer
|
|
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
|
- HY-P99430
-
|
EM901; CC-93269
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Alnuctamab (EM901) is an asymmetric 2-arm, humanized IgG T-cell engager (TCE). Alnuctamab can be used for immune research .
|
- HY-P99958
-
|
AMV-564; TandAb T564
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
|
- HY-P99676
-
|
SI-B001
|
EGFR
|
Cancer
|
|
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
|
- HY-P99675
-
|
AK112
|
PD-1/PD-L1
VEGFR
|
Cancer
|
|
Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research .
|
- HY-P99679
-
- HY-P99798
-
|
AMG 420; BI-836909
|
CD3
|
Cancer
|
|
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
|
- HY-P99802
-
|
BAY 2010112; AMG 212
|
CD3
|
Cancer
|
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
- HY-P99814
-
|
AMG-701
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
|
- HY-P99757
-
|
Hu3F8-BsAb
|
CD2
CD3
|
Cancer
|
|
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .
|
- HY-P99762
-
|
MGD009
|
CD3
|
Cancer
|
|
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
|
- HY-P99776
-
|
XmAb-13676
|
CD20
CD3
|
Cancer
|
|
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
|
- HY-P99931
-
|
GEN3013
|
CD3
CD20
|
Cancer
|
|
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
|
- HY-P99614
-
|
BFKB8488A
|
FGFR
|
Metabolic Disease
|
|
Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .
|
- HY-P990054
-
|
|
CD20
|
Cancer
|
|
Eramkafusp Alfa is a human IgG1 antibody targeting the mouse B lymphocyte CD20 antigen MS4A1 .
|
- HY-P990076
-
|
APN-301; hu14.18-IL2; EMD 273063
|
Inhibitory Antibodies
|
Cancer
|
|
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-153084
-
|
|
|
mRNA
|
|
CD19 CAR mRNA (Mouse) will express mouse CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
|
-
- HY-153084A
-
|
|
|
mRNA
|
|
CD19 CAR mRNA (Human) will express Human CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
|
-
- HY-153233
-
|
|
|
mRNA
|
|
CD19 car mRNA (Mouse)-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
